Establishment Labs Holdings Inc. (ESTA) – What Are Analysts Saying About This Stock?

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the ten analysts that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and nine have issued a buy recommendation on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $95.00.

Several analysts have recently weighed in on ESTA shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Establishment Labs in a research note on Monday, September 21st. Stifel Nicolaus initiated coverage on shares of Establishment Labs in a research report on Wednesday, October 14th. They set a “buy” rating and a $85.00 price target on the stock. Needham & Company LLC lifted their price target on shares of Establishment Labs from $86.00 to $95.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Canaccord Genuity Group set a $105.00 price objective on Establishment Labs in a report on Thursday, August 6th. Finally, JPMorgan Chase & Co. increased their price objective on Establishment Labs from $84.00 to $95.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th.

View Our Latest Research Report on Establishment Labs

Establishment Labs Trading Up 2.2%

Shares of ESTA opened at $68.52 on Tuesday. Establishment Labs has a 12-month low of $53.16 and a 12-month high of $97.59. The firm has a market capitalization of $2.04 billion, a P/E ratio of -53.53 and a beta of 1.03. The firm has a 50-day moving average price of $66.22 and a 200 day moving average price of $72.30. The company has a current ratio of 3.84, a quick ratio of 2.52 and a debt-to-equity ratio of 12.11.

Establishment Labs (NASDAQ:ESTA – Get Free Report) last issued its earnings results on Friday, October 30th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.09). Establishment Labs had a negative return on equity of 185.60% and a negative net margin of 14.56%. The firm had revenue of $71.99 million for the quarter, compared to analysts’ expectations of $66.81 million. During the same period last year, the firm earned ($0.38) earnings per share. Establishment Labs’s revenue for the quarter was up 33.8% on a year-over-year basis. Sell-side analysts forecast that Establishment Labs will post -1.18 EPS for the current year.

Institutional Investors Weigh In On Establishment Labs

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ESTA. Integrated Wealth Concepts LLC acquired a new position in shares of Establishment Labs in the 2nd quarter valued at $32,000. KBC Group NV purchased a new position in shares of Establishment Labs during the 1st quarter worth $28,000. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Establishment Labs during the 2nd quarter worth about $43,000. Sterling Capital Management LLC increased its position in shares of Establishment Labs by 849.5% during the 3rd quarter. Sterling Capital Management LLC now owns 902 shares of the company’s stock worth $58,000 after purchasing an additional 807 shares during the last quarter. Finally, State of Wyoming acquired a new stake in shares of Establishment Labs during the 2nd quarter worth about $87,000. Hedge funds and other institutional investors own 72.91% of the company’s stock.

Establishment Labs Company Profile

(Get Free Report)

Establishment Labs Holdings Inc is a medical technology company focused on breast health and aesthetics. Founded in 2004 by Juan José Chacón-Quirós, the Costa Rica-based company develops and manufactures products for breast augmentation and reconstruction.

Its product portfolio includes Motiva breast implants, offered in different shapes and designs, as well as related technologies and products for plastic and reconstructive surgery. The company also develops solutions intended to support surgical procedures and patient care.

Establishment Labs serves healthcare providers and patients in international markets, with products distributed across numerous countries.

Further Reading

Analyst Recommendations for Establishment Labs (NASDAQ:ESTA)

Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.